Methods

Data sources:
Cochrane 
Study selection and assessment:
published and unpublished randomised controlled trials (RCTs) in any language that assessed any intervention for impetigo (non-bullous, bullous, secondary, and impetiginised dermatoses) in patients with diagnosed impetigo, preferably confirmed by bacterial culture; studies that assessed patients with broadly defined bacterial skin infections or pyoderma were included if results for patients with impetigo were reported separately. 2 independent reviewers assessed the methodological quality of individual trials using the Jadad (3 items) and Delphi (9 items) scales.
Outcome:
clinical cure or improvement (eg, clearance of crusts, blisters, and redness) assessed by investigators at 1 week after initiation of treatment.
Main results
57 trials (3533 evaluable patients) met the selection criteria. 38 different treatments (20 oral and 18 topical) were assessed. 12 of 57 trials were assessed as good quality (scores of ≥50% on both quality scales).
Non-bullous impetigo. Data were sparse. Topical antibiotics (fucidic acid and mupirocin) had better cure rates than placebo, oral erythromycin, and disinfecting agents (table) . found no difference in cure rates.
Conclusions
Topical antibiotics (mupirocin or fusidic acid) may be slightly more effective than oral antibiotics (erythromycin) for patients with limited, non-bullous impetigo. Disinfecting treatments are not effective. 
A modified version of this abstract appears in Evidence-Based Nursing.
Commentary
Impetigo is a common skin infection. It is usually a minor illness that may be self limiting. Unless severe, it is managed in primary care. For many children, the problem (or perceived benefit!) is that it is contagious and necessitates a minimum of 2 days off school. The more visible, but often less serious, non-bullous form, which typically forms yellow crusts on exposed surfaces, is more commonly encountered.
Management guidance and high quality research have been in short supply. The updated systematic review by Koning et al and a recent review by George and Rubin [1] have been published in an attempt to address these deficiencies. These 2 reviews were similarly elegant and rigorous, with high concordance between chosen studies, despite minor differences in inclusion criteria. The conclusions were similar.
Mupirocin and fusidic acid appear to be the most effective topical antibiotics. They seem preferable to erythromycin in localised disease, based on both efficacy and side effects. 
